share_log

MaxCyte | 8-K: MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30%

MaxCyte | 8-K:Maxcell报告2022年第二季度和上半年财务业绩2022年第二季度核心业务收入同比增长45%将2022年核心收入增长指引提高到约30%

2022/08/10 16:15
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息